Favorable tolerability of asciminib versus ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemia. - Issa GC; Larson RA; Hughes TP; Hochhaus A; Takahashi N; Bombaci F; Wang J; Kim DW; Kim DDH; Mayer J; Goh YT; Le Coutre P; et al. (Haematologica, 2026)